Souders Financial Advisors Sells 947 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Souders Financial Advisors cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 34.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,793 shares of the biopharmaceutical company's stock after selling 947 shares during the quarter. Souders Financial Advisors' holdings in Alnylam Pharmaceuticals were worth $484,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ALNY. Park Square Financial Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $28,000. Whipplewood Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 71 shares during the last quarter. Bessemer Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 69 shares during the last quarter. Colonial Trust Co SC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $35,000. Finally, Washington Trust Advisors Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 53.5% during the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 61 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Up 1.6%

NASDAQ ALNY traded up $5.07 on Thursday, hitting $330.71. 189,424 shares of the stock were exchanged, compared to its average volume of 893,042. The company has a debt-to-equity ratio of 8.88, a quick ratio of 2.98 and a current ratio of 3.04. The stock has a fifty day moving average price of $309.80 and a two-hundred day moving average price of $273.38. The firm has a market capitalization of $43.12 billion, a P/E ratio of -158.31 and a beta of 0.23. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $333.70.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to analysts' expectations of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The firm's quarterly revenue was up 20.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.16) earnings per share. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ALNY. UBS Group increased their price objective on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Wells Fargo & Company increased their price objective on shares of Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the stock an "equal weight" rating in a research note on Monday, June 30th. JPMorgan Chase & Co. increased their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 16th. Chardan Capital increased their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Finally, Needham & Company LLC increased their price objective on shares of Alnylam Pharmaceuticals from $320.00 to $377.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-three have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $347.75.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 19,297 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the sale, the chief executive officer directly owned 48,948 shares in the company, valued at approximately $14,978,088. This trade represents a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.50% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.